Suppr超能文献

通过数字液滴PCR对接受性别不匹配造血干细胞移植的患者进行早期混合造血嵌合体检测。

Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation.

作者信息

Waterhouse Miguel, Pfeifer Dietmar, Follo Marie, Duyster Justus, Schäfer Henning, Bertz Hartmut, Finke Jürgen

机构信息

.

出版信息

Clin Chem Lab Med. 2017 Jul 26;55(8):1115-1121. doi: 10.1515/cclm-2016-0900.

Abstract

BACKGROUND

Clinical decision making after allogeneic stem cell transplantation (HSCT) is partially based on hematopoietic chimerism analysis. Polymerase chain reaction amplification of polymorphic short tandem repeats (STR-PCR) is currently considered the gold standard for chimerism surveillance after transplantation. Nevertheless, this method has shown several limitations. Emerging technologies such as digital PCR (dPCR) has been applied to detect hematopoietic chimerism. Despite previous reports, the clinical usefulness of dPCR is unclear because the studies were performed in limited patient populations with short follow-ups.

METHODS

In order to compare hematopoietic chimerism detection time and rate, we analyzed 591 samples from 155 patients undergoing gender-mismatched HSCT using STR-PCR and dPCR. We also established the correlation between both methods in artificial DNA mixtures prepared in known proportions and in clinical samples.

RESULTS

Depending on the artificial DNA mixture analyzed the correlation coefficient between both methods was 0.9946 and 0.9732. The limit of detection for dPCR was 0.01%. Of 157 samples with donor and recipient DNA, mixed chimerism (MC) was detected solely by dPCR in 66 samples. Within the group of patients relapsing after HSCT (n=32) MC was detected earlier in 15 of these patients with dPCR in comparison with STR-PCR. The mean time from MC detection to relapse was 155 days (range: 13-385 days) and 65 days (range: 0-203 days) for dPCR and STR-PCR, respectively.

CONCLUSIONS

dPCR is a sensitive and accurate method for the quantification of hematopoietic chimerism allowing earlier MC detection compared to STR-PCR.

摘要

背景

异基因造血干细胞移植(HSCT)后的临床决策部分基于造血嵌合体分析。多态性短串联重复序列的聚合酶链反应扩增(STR-PCR)目前被认为是移植后嵌合体监测的金标准。然而,该方法已显示出一些局限性。诸如数字PCR(dPCR)等新兴技术已被应用于检测造血嵌合体。尽管有先前的报道,但dPCR的临床实用性尚不清楚,因为这些研究是在有限的患者群体中进行的,随访时间较短。

方法

为了比较造血嵌合体的检测时间和率,我们使用STR-PCR和dPCR分析了155例接受性别不匹配HSCT的患者的591份样本。我们还在已知比例制备的人工DNA混合物和临床样本中建立了两种方法之间的相关性。

结果

根据所分析的人工DNA混合物,两种方法之间的相关系数分别为0.9946和0.9732。dPCR的检测限为0.01%。在157份供体和受体DNA样本中,有66份样本仅通过dPCR检测到混合嵌合体(MC)。在HSCT后复发的患者组(n = 32)中,与STR-PCR相比,dPCR在其中15例患者中更早地检测到MC。从检测到MC到复发的平均时间,dPCR为155天(范围:13 - 385天),STR-PCR为65天(范围:0 - 203天)。

结论

dPCR是一种敏感且准确的造血嵌合体定量方法,与STR-PCR相比,能够更早地检测到MC。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验